Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | CTSH | P09668 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292353 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL18328801 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL1783726 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL1783728 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL15756119 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL231491 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8387889 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8972183 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8695376 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL9234715 | 0.93 | CTSK (0.52) | CTSKALDH1A1CTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281564-A1 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | UNIV COLUMBIA (US) | 2025-09-11 | — | — | US | claimed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | claimed |
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | claimed |
| CN-119942448-A | Target person abnormal behavior prediction method based on AI | 陕西公众信息产业有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20250114368-A1 | COMPOSITIONS AND METHODS RELATING TO PEDIATRIC NEUROMUSCULAR DISEASES AND NEUROGENERATIVE DISORDERS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2025-04-10 | — | — | US | claimed |
| CN-119758340-A | High-precision positioning method based on 77GHZ vehicle millimeter wave radar | 斯达领动智能科技(苏州)有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-12233051-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | VANDERBILT UNIVERSITY (US) | 2025-02-25 | — | — | US | claimed |
| EP-4493166-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | Baylor College of Medicine (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119278032-A | Enhancement of persistent antitumor immunity by multifactorial immunomodulation | 贝勒医学院 | 2025-01-07 | — | — | CN | claimed |
| WO-2024118561-A2 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-06 | — | — | WO | claimed |
| US-20150168419-A1 | PREDICTION OF A SMALL-FOR-GESTATIONAL AGE (SGA) INFANT | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2015-06-18 | — | — | US | claimed |
| US-20130295679-A1 | PREDICTION OF A SMALL-FOR-GESTATIONAL AGE (SGA) INFANT | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2013-11-07 | — | — | US | claimed |
| EP-2641092-A1 | PREDICTION OF A SMALL-FOR-GESTATIONAL AGE (SGA) INFANT | University College Cork - National University of Ireland, Cork (IE) | 2013-09-25 | — | — | EP | claimed |
| WO-2012066057-A1 | PREDICTION OF A SMALL-FOR-GESTATIONAL AGE (SGA) INFANT | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2012-05-24 | — | — | WO | claimed |
| EP-1342085-B1 | NON-APOPTOTIC FORMS OF CELL DEATH AND METHODS OF MODULATION | BURNHAM INST (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2002101012-A9 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN S HOSPITAL RES FOUNDA (US) | 2003-12-18 | — | — | WO | claimed |
| US-20030003583-A1 | Regulation of transgene expression following AAV transduction | CHILDREN'S HOSPITAL RESEARCH FOUNDATION | 2003-01-02 | — | — | US | claimed |
| WO-2002101012-A2 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-20020111314-A1 | Novel stimulation of gene expression and protein synthesis of heat shock protein 72/73 (Hsp 70) | THE TRUSTEES OF COLUMBIA UNIVERSITY (US) | 2002-08-15 | — | — | US | claimed |
| US-5942494-A | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-08-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281564-A1 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | MAPT, PSEN1, PSEN2 | CTSK 617/4885ALDH1A1 4563/4885CTSL 1505/4885 |
| US-12233051-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | XDH, GLS, LDHA | CTSK 1120/4885ALDH1A1 121/4885CTSL 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.